title: A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.
abstract: Protein kinase C (PKC) has a critical role in several signal transduction pathways, and is involved in renal cancer pathogenesis. Bryostatin-1 modulates PKC activity and has antitumour effects in preclinical studies. We conducted a multicentre phase II clinical trial in patients with advanced renal cancer to determine the response rate, immunomodulatory activity and toxicity of bryostatin-1 given as a continuous 24 h infusion weekly for 3 out of 4 weeks at a dose of 25 mug m(-2). In all, 16 patients were recruited (11 males and five females). The median age was 59 years (range 44-68). Patients had been treated previously with nephrectomy (8) and/or interferon therapy (9) and/or hormone therapy (4) and/or radiotherapy (6). Eight, five and three patients had performance statuses of 0, 1 and 2, respectively. A total of 181 infusions were administered with a median of 12 infusions per patient (range 1-29). Disease response was evaluable in 13 patients. Three patients achieved stable disease lasting for 10.5, 8 and 5.5 months, respectively. No complete responses or partial responses were seen. Myalgia, fatigue, nausea, headache, vomiting, anorexia, anaemia and lymphopenia were the commonly reported side effects. Assessment of biological activity of bryostatin-1 was carried out using the whole-blood cytokine release assay in six patients, two of whom had a rise in IL-6 levels 24 h after initiating bryostatin-1 therapy compared to pretreatment values. However, the IL-6 level was found to be significantly lower at day 28 compared to the pretreatment level in all six patients analysed.
authors.affiliation: Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK.
authors.forename: S
authors.initials: S
authors.lastname: Madhusudan
authors.forename: A
authors.initials: A
authors.lastname: Protheroe
authors.forename: D
authors.initials: D
authors.lastname: Propper
authors.forename: C
authors.initials: C
authors.lastname: Han
authors.forename: P
authors.initials: P
authors.lastname: Corrie
authors.forename: H
authors.initials: H
authors.lastname: Earl
authors.forename: B
authors.initials: B
authors.lastname: Hancock
authors.forename: P
authors.initials: P
authors.lastname: Vasey
authors.forename: A
authors.initials: A
authors.lastname: Turner
authors.forename: F
authors.initials: F
authors.lastname: Balkwill
authors.forename: S
authors.initials: S
authors.lastname: Hoare
authors.forename: A L
authors.initials: AL
authors.lastname: Harris
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D054713:Bryostatins; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D015850:Interleukin-6 / Q000097:blood; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D018942:Macrolides; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D054713:Bryostatins; D015850:Interleukin-6; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1